Novo Nordisk A/S Stock Forecast for 2022 - 2025 - 2030

Updated on 12/01/2022

Stock Rating
18
Price Target
kr917.50
Consensus
Outperform
Upside
2.79%
Analysts
14
Stock Rating
18
Upside
2.79%
Analysts
14
Price Target
kr917.50

Novo Nordisk A/S Stock Forecast and Price Target

If the average price target of kr917.50 set by fourteen distinguished experts for Novo Nordisk A/S over the past few weeks is reached this year, there would be a potential upside of approximately 2.79% from the last closing price in December, 2022. This potential increase is based on a high estimate of kr1085.00 and a low estimate of kr540.00. If you're thinking of investing in NOVO B stock, it's critical to check out its competitors as well.

kr917.50

2.79% Upside

Outperform
Outperform

Novo Nordisk A/S Fair Value Forecast for 2022 - 2025 - 2030

In the last three years, Novo Nordisk A/S's Price has seen an increase, rising from kr366.55 to kr477.23. This represents a growth of 30.19%. For the next year, 0 analysts project Novo Nordisk A/S's Fair Value to drop by 8.32%, reaching kr437.52. By 2030, professionals believe that Novo Nordisk A/S's Fair Value will decrease by 9.20%, reaching kr433.32 – a concerning trend for the company.

2022 Fair Value Forecast
kr437.52
2023 Fair Value Forecast
kr418.37
2024 Fair Value Forecast
kr419.07
2025 Fair Value Forecast
kr437.91
2026 Fair Value Forecast
kr438.08
2027 Fair Value Forecast
kr431.49
2028 Fair Value Forecast
kr427.45
2029 Fair Value Forecast
kr430.92
2030 Fair Value Forecast
kr433.32
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 11
$178.74 $181.36 0.98%
PFE Stock Forecast Pfizer Outperform 3
$51.08 $56.27 2.39%
MRK Stock Forecast Merck Outperform 6
$109.80 $99.57 0.18%
ROG Stock Forecast Roche Holding Outperform 18
CHF310.00 CHF384.23 20.97%
AZN Stock Forecast AstraZeneca PLC Outperform 18
£112.00 £136.08 28.85%

Novo Nordisk A/S Revenue Forecast for 2022 - 2025 - 2030

In the last three years, Novo Nordisk A/S's Revenue has seen an increase, rising from kr111.83B to kr140.80B. This represents a growth of 25.90%. For the next year, 0 analysts project Novo Nordisk A/S's Revenue to drop by 7.36%, reaching kr130.44B. By 2030, professionals believe that Novo Nordisk A/S's Revenue will decrease by 7.07%, reaching kr130.84B – a concerning trend for the company.

2022 Rev Forecast
kr130.44B
2023 Rev Forecast
kr127.93B
2024 Rev Forecast
kr127.95B
2025 Rev Forecast
kr132.17B
2026 Rev Forecast
kr131.62B
2027 Rev Forecast
kr130.39B
2028 Rev Forecast
kr129.60B
2029 Rev Forecast
kr130.45B
2030 Rev Forecast
kr130.84B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
NOVN Stock Forecast Novartis Hold 18
CHF84.10 CHF103.75 7.23%
ABT Stock Forecast Abbott Laboratories Outperform 14
$107.93 $128.88 5.62%
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$80.88 $79.05 2.50%

Novo Nordisk A/S Dividend per Share Forecast for 2022 - 2025 - 2030

Novo Nordisk A/S's Dividend per Share has seen growth In the last three years, going from kr8.15 to kr10.40 – a gain of 27.61% According to 0 prominent analysts, Novo Nordisk A/S's Dividend per Share will fall by 7.71% in the next year, reaching kr9.60. By 2030, professionals believe that Novo Nordisk A/S's Dividend per Share will decrease by 8.63%, reaching kr9.50 – a concerning trend for the company.

2022 DPS Forecast
kr9.60
2023 DPS Forecast
kr9.20
2024 DPS Forecast
kr9.21
2025 DPS Forecast
kr9.59
2026 DPS Forecast
kr9.60
2027 DPS Forecast
kr9.47
2028 DPS Forecast
kr9.38
2029 DPS Forecast
kr9.45
2030 DPS Forecast
kr9.50
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
AMGN Stock Forecast Amgen Hold 7
$285.94 $246.51 -9.77%
SAN Stock Forecast Sanofi Outperform 18
87.45€ 104.66€ 22.36%
GILD Stock Forecast Gilead Sciences Outperform 9
$87.90 $69.65 -7.85%

Novo Nordisk A/S Free Cash Flow Forecast for 2022 - 2025 - 2030

Novo Nordisk A/S's Free Cash Flow has grown in the last three years, jumping from kr35.09B to kr48.67B – an increase of 38.68%. According to 0 major analysts, Novo Nordisk A/S's Free Cash Flow will fall by 10.30% in the next year, reaching kr43.65B. Professionals believe that By 2030, Novo Nordisk A/S's Free Cash Flow will fall to kr43.80B– a 10.00% decrease from its current value.

2022 FCF Forecast
kr43.65B
2023 FCF Forecast
kr41.89B
2024 FCF Forecast
kr42.46B
2025 FCF Forecast
kr44.49B
2026 FCF Forecast
kr44.24B
2027 FCF Forecast
kr43.45B
2028 FCF Forecast
kr43.13B
2029 FCF Forecast
kr43.58B
2030 FCF Forecast
kr43.80B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MDT Stock Forecast Medtronic Outperform 13
$79.25 $91.23 9.15%
CSL Stock Forecast CSL Outperform 16
$298.66 $228.01 -28.44%
GSK Stock Forecast GSK Outperform 16
£14.15 £16.08 14.13%

Novo Nordisk A/S Net Income Forecast for 2022 - 2025 - 2030

In the last three years, Net Income for Novo Nordisk A/S has grown by 23.63%, going from kr38.63B to kr47.76B. In the following year, 0 experts forecast Novo Nordisk A/S's Net Income will decrease by 6.72%, to kr44.55B. In 2030, professionals predict that Novo Nordisk A/S's Net Income will decrease by 7.90%, to kr43.99B.

2022 NI Forecast
kr44.55B
2023 NI Forecast
kr42.75B
2024 NI Forecast
kr42.70B
2025 NI Forecast
kr44.34B
2026 NI Forecast
kr44.43B
2027 NI Forecast
kr43.87B
2028 NI Forecast
kr43.48B
2029 NI Forecast
kr43.77B
2030 NI Forecast
kr43.99B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BSX Stock Forecast Boston Scientific Outperform 15
$46.12 $49.85 5.16%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.60k ¥0.00 13.12%
SHW Stock Forecast Sherwin Williams Outperform 15
$251.61 $255.48 4.92%

Novo Nordisk A/S EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, Novo Nordisk A/S's EBITDA has increased by 24.19%, going from kr51.17B to kr63.55B. In the next year, 0 analysts estimate that Novo Nordisk A/S's EBITDA will decrease by 6.94%, reaching kr59.14B. According to professional forecasts, in 2030, Novo Nordisk A/S's EBITDA will decrease by 6.26%, reaching kr59.57B.

2022 EBITDA Forecast
kr59.14B
2023 EBITDA Forecast
kr58.31B
2024 EBITDA Forecast
kr58.51B
2025 EBITDA Forecast
kr60.18B
2026 EBITDA Forecast
kr59.84B
2027 EBITDA Forecast
kr59.33B
2028 EBITDA Forecast
kr59.07B
2029 EBITDA Forecast
kr59.44B
2030 EBITDA Forecast
kr59.57B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BAYN Stock Forecast Bayer Outperform 7
55.03€ 67.79€ 43.56%
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 16
¥4.03k ¥0.00 7.86%
BIIB Stock Forecast Biogen Outperform 11
$301.85 $242.78 7.67%

Novo Nordisk A/S EBIT Forecast for 2022 - 2025 - 2030

In the last three years, Novo Nordisk A/S's EBIT has grown, increasing from kr47.25B to kr59.34B – an increase of 25.59%. According to 0 analysts, Novo Nordisk A/S's EBIT will fall by 7.28% in the next year, reaching kr55.02B. Professionals believe that By 2030, Novo Nordisk A/S's EBIT will fall to kr55.48B – a 6.50% decrease from its current value.

2022 EBIT Forecast
kr55.02B
2023 EBIT Forecast
kr54.29B
2024 EBIT Forecast
kr54.47B
2025 EBIT Forecast
kr56.08B
2026 EBIT Forecast
kr55.73B
2027 EBIT Forecast
kr55.25B
2028 EBIT Forecast
kr55.00B
2029 EBIT Forecast
kr55.36B
2030 EBIT Forecast
kr55.48B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
PPG Stock Forecast PPG Industries Outperform 13
$134.96 $135.05 -7.38%
ALNY Stock Forecast Alnylam Pharmaceuticals Outperform 7
$220.25 $236.31 8.06%
HZNP Stock Forecast Horizon Therapeutics Public Buy 16
$100.88 $0.00 38.78%

Novo Nordisk A/S EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the last three years, Novo Nordisk A/S's EPS has seen an increase, rising from kr15.93 to kr20.74. This represents a growth of 30.19%. For the next year, 0 analysts project Novo Nordisk A/S's EPS to drop by 8.32%, reaching kr19.01. By 2030, professionals believe that Novo Nordisk A/S's EPS will decrease by 9.20%, reaching kr18.83 – a concerning trend for the company.

2022 EPS Forecast
kr19.01
2023 EPS Forecast
kr18.18
2024 EPS Forecast
kr18.21
2025 EPS Forecast
kr19.03
2026 EPS Forecast
kr19.04
2027 EPS Forecast
kr18.75
2028 EPS Forecast
kr18.58
2029 EPS Forecast
kr18.73
2030 EPS Forecast
kr18.83
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
IPN Stock Forecast Ipsen Hold 17
107.20€ 94.86€ 0.75%
500124 Stock Forecast Dr. Reddy's Laboratories Outperform 18
Rp4.47k Rp5.47k 10.68%
GRF Stock Forecast Grifols Outperform 18
10.55€ 27.25€ 100.95%